Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Reuters02-15

* Citius Pharmaceuticals Inc reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December. The lone analyst forecast for the quarter was for earnings of 13 cents per share.

* Reported revenue was zero; analysts expected $21.30 million.

* Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents.

* The company reported a quarterly loss of $9.23 million.

* Citius Pharmaceuticals Inc shares had fallen by 10.1% this quarter.

FORECAST CHANGES

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $4.00 This summary was machine generated from LSEG data February 14 at 11:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Dec. 31 2023 0.13 -0.06 Missed

Sep. 30 2023 -0.02 -0.08 Missed

Jun. 30 2023 -0.05 -0.06 Missed

Mar. 31 2023 -0.03 -0.07 Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2411466556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-15 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2411466556","market":"us","top_or_hot":-1,"title":"Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary","media":"Reuters","content":"<html><body><p>* Citius Pharmaceuticals Inc    reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December.  The lone analyst forecast for the quarter was for earnings of 13 cents per share. </p><p>   * Reported revenue was zero; analysts expected $21.30 million. </p><p>   * Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents.</p><p>   * The company reported a quarterly loss of $9.23 million.</p><p>   * Citius Pharmaceuticals Inc shares had fallen by 10.1% this quarter.</p><p>FORECAST CHANGES</p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" </p><p>   * The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"buy\"</p><p>Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $4.00  This summary was machine generated from LSEG data February 14 at 11:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Dec. 31 2023      0.13           -0.06          Missed</p><p>Sep. 30 2023      -0.02          -0.08          Missed</p><p>Jun. 30 2023      -0.05          -0.06          Missed</p><p>Mar. 31 2023      -0.03          -0.07          Missed</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-15 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Citius Pharmaceuticals Inc    reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December.  The lone analyst forecast for the quarter was for earnings of 13 cents per...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2411466556","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2411466556","pubTimestamp":1707955070,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Citius Pharmaceuticals Inc    reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December.  The lone analyst forecast for the quarter was for earnings of 13 cents per s","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"花旗制药公司报告截至12月的季度业绩——收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9},"content_text":"* Citius Pharmaceuticals Inc    reported a quarterly adjusted loss of 6 cents per share for the quarter ended in December.  The lone analyst forecast for the quarter was for earnings of 13 cents per share.    * Reported revenue was zero; analysts expected $21.30 million.    * Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents.   * The company reported a quarterly loss of $9.23 million.   * Citius Pharmaceuticals Inc shares had fallen by 10.1% this quarter.FORECAST CHANGES   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"    * The average consensus recommendation for the biotechnology & medical research peer group is also \"buy\"Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $4.00  This summary was machine generated from LSEG data February 14 at 11:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDDec. 31 2023      0.13           -0.06          MissedSep. 30 2023      -0.02          -0.08          MissedJun. 30 2023      -0.05          -0.06          MissedMar. 31 2023      -0.03          -0.07          Missed","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2411466556"}